| Walking avoids prostate cancer bone loss
LOS ANGELES, Oct. 29 Prostate cancer patients are not routinely advised to exercise, but a U.S. study found walking prevents bone loss caused from prostate cancer treatment.
Lead author Paula Chiplis of The Johns Hopkins Hospital in Baltimore said men with prostate cancer frequently receive radiation therapy to kill the cancer cells followed by months of hormone therapy, which decreases testosterone and estrogen that feed cancer cells.
Men undergoing hormone therapy lose between 4 percent to 13 percent of their bone density annually, compared to healthy men who lose from 0.5 percent to 1 percent per year, beginning in middle age.
The study involved 70 sedentary men with prostate cancer randomly assigned to a nurse-directed, home-based walking program or usual care -- no exercise during radiation treatment, with more than half also receiving hormone therapy.
Androgen Deprivation Therapy-induced Fractures in Men With ...
Androgen deprivation therapy (ADT), such as orchiectomy or gonadotropin-releasing hormone agonist therapy, is increasingly used for the treatment of localized, high-risk, or biochemical relapse of prostate cancer. Bone mineral density loss is associated with ADT, presenting an increased risk for fractures, and strategies for preventing bone loss include antiresorptive therapy and lifestyle changes, such as smoking cessation and reduced alcohol consumption. Androgen Deprivation Therapy-induced Fractures in Men With Nonmetastatic Prostate Cancer: What Do We Really Know?
Celestia S. Higano, MD
Go to Test Questions .
Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT ...
SEATTLE, Oct. 23 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced that the Company has completed enrollment of over 500 patients in the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. The IMPACT study is a double-blind, randomized, placebo-controlled Phase 3 trial designed to measure overall survival in men with metastatic hormone-refractory prostate cancer receiving PROVENGE versus placebo. Earlier this year, following a positive recommendation from an outside panel of experts, Dendreon received a complete response letter from the U.S. Food and Drug Administration (FDA) that asked for additional evidence that would support the efficacy of PROVENGE.
|
